Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

abstract：:We estimated the cost effectiveness of adding the ACE inhibitor ramipril to conventional treatment in patients with heart failure after acute myocardial infarction. These estimates were based on the Acute Infarction Ramipril Efficacy (AIRE) study and on complementary Swedish healthcare resource use data for a subset o...

journal_title：PharmacoEconomics

authors： Erhardt L,Ball S,Andersson F,Bergentoft P,Martinez C

更新日期：1997-08-01 00:00:00

abstract：:The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements fo...

journal_title：PharmacoEconomics

authors： Oostenbrink JB,Koopmanschap MA,Rutten FF

更新日期：2002-01-01 00:00:00

abstract：:Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article. ...

journal_title：PharmacoEconomics

authors： Wehler E,Boytsov N,Nicolay C,Herrera-Restrepo O,Kowal S

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:During the 1990s, a number of new cytotoxic agents with clinically relevant activity in non-small-cell lung cancer (NSCLC), and with a more favourable therapeutic index than drugs already in use, became available. Given the high prices of these new drugs and the large number of patients affected, it is impor...

journal_title：PharmacoEconomics

authors： Neymark N,Lianes P,Smit EF,van Meerbeeck JP

更新日期：2005-01-01 00:00:00

abstract：:Variable compliance with prescribed drug regimens is a leading source of variability in drug response. Specifics differ by drug and disease. The role of variable compliance was clearly defined in 2 trials of lipid-lowering agents, cholestyramine and gemfibrozil, in which exceptionally careful measurements of complianc...

journal_title：PharmacoEconomics

authors： Urquhart J

更新日期：1999-03-01 00:00:00

abstract：BACKGROUND:In Ireland, all new drugs are considered for a formal pharmacoeconomic evaluation (PE) prior to a reimbursement decision. All evaluations are conducted by the National Centre for Pharmacoeconomics (NCPE). The objectives of this study were to describe the evaluation process and to examine the movement of drug...

journal_title：PharmacoEconomics

authors： McCullagh L,Barry M

更新日期：2016-12-01 00:00:00

abstract：OBJECTIVE:To estimate the annual direct cost of managing erectile dysfunction (ED) to the UK National Health Service (NHS) and to examine the impact of the introduction of sildenafil in 1998 and Schedule 11 restrictions in 1999. DESIGN:A prevalence-based cost-of-illness approach was used. The period 1997 to 2000 was c...

journal_title：PharmacoEconomics

authors： Wilson EC,McKeen ES,Scuffham PA,Brown MC,Wylie K,Hackett G

更新日期：2002-01-01 00:00:00

abstract：:Currently, the most important issue in US pharmaceutical policy is probably cost containment. Research into pharmaceutical issues should therefore concentrate on this area. Analysis of changing trends in pharmaceutical expenditures, particularly during the early 1990s, would be a useful starting point. Research into t...

journal_title：PharmacoEconomics

authors： Meyer PR

更新日期：1996-01-01 00:00:00

abstract：BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...

journal_title：PharmacoEconomics

authors： Meads DM,Marshall A,Hulme CT,Dunn JA,Ford HE

更新日期：2016-01-01 00:00:00

abstract：:Migraine headache is responsible for significantly more healthcare resource and lost labour costs than previously reported. Costs associated with migraine were assessed via a survey conducted in 940 patients, 70% of whom responded. All met the International Headache Society's diagnostic criteria for migraine and had ...

journal_title：PharmacoEconomics

authors： Osterhaus JT,Gutterman DL,Plachetka JR

更新日期：1992-07-01 00:00:00

abstract：:Cefotaxime is a parenterally administered third generation cephalosporin with a broad spectrum of antimicrobial activity. After more than a decade of use, cefotaxime continues to play an important role in the treatment of patients with serious infections, particularly those caused by Gram-negative bacteria. Clinical t...

journal_title：PharmacoEconomics

authors： Plosker GL,Foster RH,Benfield P

更新日期：1998-01-01 00:00:00

abstract：OBJECTIVE:To estimate indirect costs in Spanish ambulatory patients with HIV/AIDS and to identify changes in employment status and their current QOL. METHOD:Information was obtained through 32 interviews/enquiries carried out with ambulatory patients receiving medical attention at Gregorio Marañón and Puerta de Hierro...

journal_title：PharmacoEconomics

authors： Oliva J,Roa C,del Llano J

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Cost-effectiveness analyses worldwide assume that the price of any single drug increases with inflation. New guidance from the Pharmaceutical Management Agency in New Zealand suggests that, when it is known that a generic drug will be available in the near future, a best estimate of the lower price of the ge...

journal_title：PharmacoEconomics

authors： Hoyle M

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:The response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix®, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications. O...

journal_title：PharmacoEconomics

authors： Najafzadeh M,Garces JA,Maciel A

更新日期：2017-12-01 00:00:00

abstract：:Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...

journal_title：PharmacoEconomics

authors： Chongmelaxme B,Phisalprapa P,Manthaisong R,Dilokthornsakul P,Chaiyakunapruk N

更新日期：2019-02-01 00:00:00

abstract：OBJECTIVE:To evaluate the cost effectiveness of dabrafenib versus dacarbazine and vemurafenib as first-line treatments in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a Canadian healthcare system perspective. METHODS:A partitioned-survival analysis model with three mutually exclus...

journal_title：PharmacoEconomics

authors： Delea TE,Amdahl J,Wang A,Amonkar MM,Thabane M

更新日期：2015-04-01 00:00:00

abstract：BACKGROUND:In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Terkola R,Overton PM,Shalet N,Postma M

更新日期：2017-08-01 00:00:00

abstract：BACKGROUND:Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Administration and pharmaceutical companies around the price of new pharmaceuticals. The criteria currently...

journal_title：PharmacoEconomics

authors： Ochalek J,Wang H,Gu Y,Lomas J,Cutler H,Jin C

更新日期：2020-12-01 00:00:00

abstract：:Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy in patients with LGS uncontrolled on one to t...

journal_title：PharmacoEconomics

authors： McCormack PL

更新日期：2012-03-01 00:00:00

abstract：:Epidural analgesia and intravenous analgesia with opioids are two techniques for providing pain relief for women in labour. Labour pain is comparable to surgical pain in its severity, and epidural analgesia provides better relief from this pain than intravenous analgesia; a meta-analysis quantified this improvement to...

journal_title：PharmacoEconomics

authors： Huang C,Macario A

更新日期：2002-01-01 00:00:00

abstract：:Potential conflict between the goals of the investigators and the sponsors of pharmacoeconomic and clinical research has been well documented. Although there have been efforts to formalise relationships between sponsors and investigators in some areas of clinical research, no set of guidelines or standardised contract...

journal_title：PharmacoEconomics

authors： Schulman KA,Rubenstein LE,Glick HA,Eisenberg JM

更新日期：1995-03-01 00:00:00

abstract：OBJECTIVE:To decompose drug spending in Sweden between the years 1990 and 2000. This paper updates a previous study, which looked at the period 1990-1995, by providing an additional 5 years of data (1995-2000) and extending the previous analysis in a number of ways. METHODS:The paper builds on the earlier work that sh...

journal_title：PharmacoEconomics

authors： Gerdtham UG,Lundin D

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Assessing the societal perspective in economic evaluations of new interventions requires estimates of indirect non-medical costs caused by the disease. Different methods exist for measuring the labor input function as a surrogate for these costs. They rarely specify the effect of health on labor and who gain...

journal_title：PharmacoEconomics

authors： Standaert B,Sauboin C,Leclerc QJ,Connolly MP

更新日期：2020-11-25 00:00:00

abstract：:Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a ...

journal_title：PharmacoEconomics

authors： Yang BM

更新日期：2009-01-01 00:00:00

abstract：:Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

journal_title：PharmacoEconomics

authors： Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

更新日期：1997-08-01 00:00:00

abstract：:Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN tri...

journal_title：PharmacoEconomics

authors： Mauskopf J,Annemans L,Hill AM,Smets E

更新日期：2010-01-01 00:00:00

abstract：:The progressive increase in the prevalence of obesity and aging in the population is resulting in increased healthcare and disability spending. The burden of obesity is particularly relevant in old age, due to accumulating co-morbidities and changes in body composition. Sarcopenic obesity, a mix of over- and under-nut...

journal_title：PharmacoEconomics

authors： Corica F,Bianchi G,Corsonello A,Mazzella N,Lattanzio F,Marchesini G

更新日期：2015-07-01 00:00:00

abstract：:The regulation of pricing and trade for in-patent medicines within the European pharmaceutical sector presents a major challenge. In conditions of large sunk costs and consumers with differential willingness to pay--between different Member States--an efficient way of pricing in-patent medicines is through price discr...

journal_title：PharmacoEconomics

authors： Glynn D

更新日期：2000-01-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic, generally progressive autoimmune disease that causes functional disability, significant pain and joint destruction, and leads to premature mortality. It is estimated to affect between 0.5 and 1.0% of the adult population worldwide, increases in prevalence with age and affects mo...

journal_title：PharmacoEconomics

authors： Kvien TK

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Probabilistic sensitivity analysis (PSA) in cost-effectiveness analysis involves sampling a large number of realisations of an economic model. For some parameters, we may be uncertain around the true mean values of the variables, but the ordering of the values is known. Typical sampling approaches lack eithe...

journal_title：PharmacoEconomics

authors： Ren S,Minton J,Whyte S,Latimer NR,Stevenson M

更新日期：2018-03-01 00:00:00